Efficacy and safety of ritonavir-boosted danoprevir combined with daclatasvir in treatment of patients with genotype 1b chronic hepatitis C
10.3760/cma.j.issn.1674-2397.2019.05.005
- VernacularTitle:利托那韦强化的达诺瑞韦联合达拉他韦治疗1b 型慢性丙型肝炎的临床疗效分析
- Author:
Wencheng LI
1
;
Shanfei GE
;
Xiaoping WU
;
Yangyang DENG
;
Lingjun XU
;
Liang WANG
;
Ying XIONG
Author Information
1. 南昌大学第一附属医院感染科330006
- Keywords:
Hepatitis C,chronic;
Danoprevir;
Daclatasvir;
Ritonavir;
Efficacy
- From:
Chinese Journal of Clinical Infectious Diseases
2019;12(5):350-353,371
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of ritonavir-boosted danoprevir (DNVr) combined with daclatasvir (DCV) in the treatment of patients with genotype 1b chronic hepatitis C (CHC).Methods Thirty-three patients with genotype 1b CHC admitted in the Department of Infectious Diseases of the First Affiliated Hospital of Nanchang University from August 2018 to February 2019 were enrolled.All the patients received DNVr +DCV antiviral treatment.HCV RNA levels were detected before and 2, 4, 12 weeks after treatment, and after drug withdrawal , respectively.Indicators of liver and kidney function and adverse events were observed.ANOVAV of repeated measurement was used to analyze the data. Results The baseline viral loads of 33 patients ranged from 1.12×104 to 1.76×107 IU／mL.Two weeks after treatment the viral loads of all patients were down to the lowest limit of detection (＜500 IU／mL). Serum ALT, AST and TBil levels returned to norml ( F＝58.26, 14.49 and 20.16, all P＜0.05) and sustained virologic response reached 100%12 weeks after drug withdrawal.Three cases had minor adverse reactions during the treatment.Conclusion DNVr combined with DCV can achieve a rapid and strong virological response in the treatment of patients with genotype 1b CHC with good safety.
